If that same ratio from LL EIND treatment at UCLA (mortality = 6/31=19.4%) holds for current Phase III trial, then of the 130 in LL arm at interim analysis, 25 should have passed. That leaves 20/65 in placebo arm, 30.8%.

Lowering ~30% mortality rate by ~1/3 to ~20% should be a winner, but perhaps we would need to finish the trial to make sure it holds.